References
1El-Naggar AK: Editor’s perspective on the 4th edition of the WHO head and neck tumor classification. J Egypt Natl Cancer 2017;29:65–66.
2Llorente JL, Lopez F, Suarez C, Hermsen MA: Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances. Nat Rev Clin Oncol 2014;11:460–472.
3Youlden DR, Cramb SM, Peters S, et al: International comparisons of the incidence and mortality of sinonasal cancer. Cancer Epidemiol 2013;37:770–779.
4Robin PE, Powell DJ, Stansbie JM: Carcinoma of the nasal cavity and paranasal sinuses: incidence and presentation of different histological types. Clin Otolaryngol Allied Sci 1979;4:431–456.
5Sanghvi S, Khan MN, Patel NR, Yeldandi S, Baredes S, Eloy JA: Epidemiology of sinonasal squamous cell carcinoma: a comprehensive analysis of 4,994 patients. Laryngoscope 2014;124:76–83.
6Turner JH, Reh DD: Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck 2012;34:877–885.
7Jeng YM, Sung MT, Fang CL, et al: Sinonasal undifferentiated carcinoma and nasopharyngeal-type undifferentiated carcinoma: two clinically, biologically, and histopathologically distinct entities. Am J Surg Pathol 2002;26:371–376.
8Zong Y, Liu K, Zhong B, Chen G, Wu W: Epstein-Barr virus infection of sinonasal lymphoepithelial carcinoma in Guangzhou. Chin Med J 2001;114:132–136.
9Rytkonen AE, Hirvikoski PP, Salo TA: Lymphoepithelial carcinoma: two case reports and a systematic review of oral and sinonasal cases. Head Neck Pathol 2011;5:327–334.
10Wenig BM: Lymphoepithelial-like carcinomas of the head and neck. Semin Diagn Pathol 2015;32:74–86.
11Reiersen DA, Pahilan ME, Devaiah AK: Meta-analysis of treatment outcomes for sinonasal undifferentiated carcinoma. Otolaryngol Head Neck Surg 2012;147:7–14.
12Chambers KJ, Lehmann AE, Remenschneider A, et al: Incidence and survival patterns of sinonasal undifferentiated carcinoma in the United States. J Neurol Surg B Skull Base 2015;76:94–100.
13Chernock RD, Perry A, Pfeifer JD, Holden JA, Lewis JS Jr: Receptor tyrosine kinases in sinonasal undifferentiated carcinomas – evaluation for EGFR, c-KIT, and HER2/neu expression. Head Neck 2009;31:919–927.
14Gray ST, Herr MW, Sethi RK, et al: Treatment outcomes and prognostic factors, including human papillomavirus, for sinonasal undifferentiated carcinoma: a retrospective review. Head Neck 2015;37:366–374.
15Bossi P, Saba NF, Vermorken JB, et al: The role of systemic therapy in the management of sinonasal cancer: a critical review. Cancer Treat Rev 2015;41:836–843.
16Yoshida E, Aouad R, Fragoso R, et al: Improved clinical outcomes with multi-modality therapy for sinonasal undifferentiated carcinoma of the head and neck. Am J Otolaryngol 2013;34:658–663.
17Bauer DE, Mitchell CM, Strait KM, et al: Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 2012;18:5773–5779.
18Chau NG, Mitchell CM, Aserlind A, et al: Aggressive treatment and survival outcomes in NUT midline carcinoma (NMC) of the head and neck (HN). J Clin Oncol 2014;32:6057.
19Solomon LW, Magliocca KR, Cohen C, Muller S: Retrospective analysis of nuclear protein in testis (NUT) midline carcinoma in the upper aerodigestive tract and mediastinum. Oral Surg Oral Med Oral Pathol Oral Radiol 2015;119:213–220.
20Rutt AL, Poulik J, Siddiqui AH, et al: NUT midline carcinoma mimicking tonsillitis in an eight-year-old girl. Ann Otol Rhinol Laryngol 2011;120:546–549.
21Haack H, Johnson LA, Fry CJ, et al: Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol 2009;33:984–991.
22French CA: Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 2012;7:247–265.
23French CA, Kutok JL, Faquin WC, et al: Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol 2004;22:4135–4139.
24Suzuki S, Kurabe N, Ohnishi I, et al: NSD3-NUT-expressing midline carcinoma of the lung: first characterization of primary cancer tissue. Pathol Res Pract 2015;211:404–408.
25Patel TD, Vazquez A, Dubal PM, Baredes S, Liu JK, Eloy JA: Sinonasal neuroendocrine carcinoma: a population-based analysis of incidence and survival. Int Forum Allergy Rhinol 2015;5:448–453.
26Smith SR, Som P, Fahmy A, Lawson W, Sacks S, Brandwein M: A clinicopathological study of sinonasal neuroendocrine carcinoma and sinonasal undifferentiated carcinoma. Laryngoscope 2000;110:1617–1622.
27Chai L, Ying HF, Wu TT, et al: Clinical features and hypoxic marker expression of primary sinonasal and laryngeal small-cell neuroendocrine carcinoma: a small case series. World J Surg Oncol 2014;12:199.
28Mitchell EH, Diaz A, Yilmaz T, et al: Multimodality treatment for sinonasal neuroendocrine carcinoma. Head Neck 2012;34:1372–1376.
29Su SY, Bell D, Hanna EY: Esthesioneuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma: differentiation in diagnosis and treatment. Int Arch Otorhinolaryngol 2014;18(suppl 2):S149–S156.
30Babin E, Rouleau V, Vedrine PO, et al: Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses. J Laryngol Otol 2006;120:289–297.
31Likhacheva A, Rosenthal DI, Hanna E, Kupferman M, Demonte F, El-Naggar AK: Sinonasal neuroendocrine carcinoma: impact of differentiation status on response and outcome. Head Neck Oncol 2011;3:32.
32Vasan NR, Medina JE, Canfield VA, Gillies EM: Sinonasal neuroendocrine carcinoma in association with SIADH. Head Neck 2004;26:89–93.
33Weinreb I, Perez-Ordonez